Origin of ovarian cancer: Molecular profiling

Journal of Obstetrics and Gynecology of India

Volumn 63, Issue 3, 2013, Pages 152-157

  Dutta, Dilip Kumar ^a   Dutta, Indranil ^a  

^a Gice Hospital A 9 7   (India)

Author keywords

Molecular profiling; Ovarian cancer; Targeted therapy

Indexed keywords

TRASTUZUMAB;

CANCER DIAGNOSIS; CANCER SCREENING; EVIDENCE BASED MEDICINE; HUMAN; MICROENVIRONMENT; MOLECULAR DIAGNOSIS; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 84890313476     PISSN: 09719202     EISSN: 09756434     Source Type: Journal    
DOI: 10.1007/s13224-013-0419-x     Document Type: Review

References (25)

1. Reiss A, Walter H, lieb G. On the original ovarian and endometrial cancer: molecular profiling of gynecologic cancer. Recent Adv Gyne Oncol. 2010;10:134-44.
2. Fukumoto M, Nakayama K. Ovarian epithelial tumors of low malignant potential: Are they precursors of ovarian carcinoma? Pathol Int. 2006;56:233-9.
3. Gotlieb WH, Friedman E, Bar-Sade RB, et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst. 1998;90:995-1000.
4. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64:6915-8.
5. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27:151-60.
6. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-9.
7. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-43.
8. Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008;5:577-87.
9. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814-24.
10. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
11. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550-60.
12. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924-30.
13. Mandai M, Yamaguchi K, Mastumura N, et al. 2010 IGCS meeting Prague, abstract page 24, http://journals.lww.com/ijgc/Documents/ IGCS%2013%20Meeting%20Abstracts,%20Prague.pdf.
14. McAlpine JN, Wiegand KC, Vang R, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433.
15. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2005;24:1053-65.
16. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11:6116-26.
17. Murphy MA, Wentzensen N. Frequency of mismatch repair deficiency in ovarian cancer: a systematic review. Int J Cancer. 2010;129(8):1914-22.
18. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008;8:17.
19. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev. 1996;5:933-5.
20. Scully RE. Ovarian tumors. A review.Am J Pathol. 1977;87:686-720.
21. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223-8.
22. Signorelli M, Fruscio R, Lissoni AA, et al. Synchronous early-stage endometrial and ovarian cancer. Int J Gynaecol Obstet. 2008;102:34-8.
23. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-9.
24. Vicus D, Shaw PA, Finch A, et al. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. Gynecol Oncol. 2010;118:295-8.
25. Wong KK, Tsang YT, Deavers MT, et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010;177:1611-7.